Shuoshi Bio (688399): Earnings at a Low Point, Accelerated Layout Across Multiple Platforms

The company's performance has stabilized, with its diagnostic reagent business demonstrating strong resilience. In 2025, the company achieved operating revenue of 340 million yuan, representing a year-on-year decrease of 3.0%, and net profit attributable to shareholders was -40 million yuan. In the fourth quarter of 2025, the company generated operating revenue.

Orient SecuritiesMay 14 13:31

Express News | The concept of virus prevention and control remains highly active, with Kaipu Bio rising over 13%.

BreakingsMay 11 09:46

Shuoshi Bio (688399.SH) has obtained a medical device registration certificate.

Shuoshi Bio (688399.SH) announced that the company has recently received a medical device registration certificate (in vitro diagnostic reagent) issued by the National Medical Products Administration. The product name is: Influenza A H1N1 (2009) and Seasonal H3 Subtype Influenza Virus Nucleic Acid Detection Kit (Fluorescent PCR Method). This kit is used for the in vitro qualitative detection of nucleic acids of Influenza A H1N1 (2009) and Seasonal H3 Subtype Influenza Virus in human throat swab samples.

Zhitong FinanceMay 6 17:48

Shuoshi Biotechnology: First Quarter Report for 2026 of Jiangsu Shuoshi Biotechnology Co., Ltd.

SZSIApr 30 00:00 · Announcements

Jiangsu Shuoshi Biotechnology Co., Ltd. First Quarter Report for 2026

SZSIApr 30 00:00 · Announcements

Shuoshi Bio (688399.SH) reported a net profit of 21.1222 million yuan in the first quarter, representing a year-on-year increase of 64.77%.

Gelonghui reported on April 29 that the Q1 2026 financial report released by Shuoshi Bio (688399.SH) showed that the company achieved operating revenue of RMB 78.584 million in the first quarter, a year-on-year decrease of 14.22%; net profit attributable to shareholders of RMB 21.1222 million, a year-on-year increase of 64.77%; and non-recurring net profit attributable to shareholders of -RMB 4.0122 million.

Gelonghui FinanceApr 29 19:15